MAIA Biotechnology Activates First U.S. Site for Phase 2 NSCLC Trial

What Happened

• On April 16, 2026, MAIA Biotechnology, Inc. announced via press release that it has activated the first U.S. site in its ongoing international Phase 2 expansion trial of a novel telomere‑targeting treatment for advanced non‑small cell lung cancer (NSCLC). The press release is attached to the Form 8‑K as Exhibit 99.1.

Key Details

• Date filed: April 16, 2026.
• Event: Activation of the first U.S. clinical site for the international Phase 2 expansion trial targeting advanced NSCLC.
• Therapy focus: Novel telomere‑targeting treatment (clinical development stage).
• Filing includes standard forward‑looking statements cautioning investors about risks related to study timing, costs, results, regulatory approvals, manufacturing, market acceptance, intellectual property and U.S. site expansion/talent sourcing.

Why It Matters

• The activation of a U.S. site signals progress in MAIA’s clinical development and U.S. expansion for its Phase 2 program, which may affect trial enrollment and timelines. The filing does not report financial results or regulatory approvals; it primarily provides a corporate update and reiterates standard risk disclosures related to clinical and operational uncertainty.